Kornimate/medical-research-clean huggingface dataset:
clinical results and restenosis analysis of symptomatic ostial vertebral artery stenosis treated with tubular coronary stents

Conditions: Vertebral Artery Stenosis

Summary: vertebral artery stenosis (vas) decreases posterior brain perfusion, causing vertebrobasilar insufficiency (vbi). it is also an important embolic source to the posterior brain. the most frequently involved location is the proximal part of the vessel, including the ostium. various surgical procedures have been described for the treatment of proximal vas with symptoms refractory to medical therapy, but all are technically difficult with high operative mortality and morbidity. endovascular intervention has been described as an alternative to surgery. balloon angioplasty is limited by elastic recoil and dissection. the restenosis rates reported in the literature varied, as high as 75 %. stenting offers salvage following unsuccessful balloon angioplasty, and primary stenting have been shown to be safe and effective with lower restenosis rate. coronary equipments are ideal for ostial vas, considering the size of the artery and location of the lesion. recently, albuquerque et al. reports a relative high restenosis rate in a longer follow-up duration. restenosis seems to become an important issue regarding the patients' quality of life. however, there is no clinical parameter to predict restenosis of vas. the purpose of this study is to evaluate the clinical results of our series of symptomatic ostial vas treated exclusively with tubular balloon expandable coronary stents. we sought to identify predictors of restenosis. this is a clinical observation study. only chart review and angiographic review will be performed.


Eligibility criteria:
inclusion criteria: patients with symptomatic vertebral artery stenosis treated by stenting exclusion criteria: -
effects of probiotics (biokid lr - contains nine different species of probiotics bacteria including l. reuteri) in children with functional constipation

Conditions: Constipation

Summary: the goal of this clinical trial is to evaluate whether a probiotic supplement, biokid lr®, can help maintain normal bowel movements after stopping laxative treatment (peg 3350) in children aged 6 months to 17 years with functional constipation. the main questions it aims to answer are: does taking biokid lr reduce the chance of constipation coming back after stopping peg? can biokid lr help children maintain regular bowel movements without needing to restart laxatives? researchers will compare children who take biokid lr with those who take a placebo (an inactive powder) to see if the probiotic helps prevent constipation from returning. participants will: take peg 3350 (a common laxative) for 12 weeks along with either biokid lr or a placebo. after 12 weeks, begin gradually stopping peg while continuing with biokid lr or placebo for another 12 weeks. then continue only with biokid lr or placebo for an additional 28 weeks (total study duration: 52 weeks). keep a stool diary to track bowel habits and any side effects. attend 5 study visits for physical exams and monitoring (weeks 0, 12, 24, 38, 52). the study includes 80 children and is double-blinded, meaning neither the doctors nor the participants know who is receiving the real probiotic or the placebo. the primary outcome is how long it takes for constipation to return after stopping peg, requiring retreatment. secondary outcomes include: how many children still need long-term treatment. how many have regular bowel movements without accidents (in children over 4 years old). stool consistency and frequency. children with certain medical conditions (like celiac disease or hypothyroidism) or who are taking medications that cause constipation cannot participate. this study is supported by supherb group, israel, but they are not involved in designing or analyzing the research. the study has been approved by an ethics committee and follows international ethical guidelines.


Eligibility criteria:
inclusion criteria: 1. age 0.5 - 17 years 2. diagnosis of fc based on rome iv criteria exclusion criteria: 1. children with chronic diseases which could cause constipation: celiac disease, food allergy, hypothyroidism, inflammatory bowel disease, electrolytes disturbances, cystic fibrosis, hirschsprung disease, neuropathic conditions (spinal cord trauma, neurofibromatosis, tethered cord) or intestinal pseudo-obstruction 2. prematurity (\<34 weeks) 3. s/p intestinal surgery 4. immunodeficiency 5. malignancy 6. children treated with medications associated with constipation. \*

Keywords: constipation laxatives peg 350
treatment response and prognosis in glioma patients: q cell and its biological characteristics

Conditions: Glioblastoma; Malignant Glioma

Summary: the purpose of this study is to determine whether q cells separated from the glioma sample are determinants in treatment response and prognosis of glioma patients

the unique markers of qcell were screened using the method of genomics and proteomics, then these markers will be qualitatively and quantitatively evaluated in glioblastoma patients by comparing their relationship with overrall survival/progression-free survival and treatment response.

Eligibility criteria:
inclusion criteria: 1. \>=18 years old 2. primary glioblastoma is newly diagnosed and confirmed histologically 3. patient is expected to be treated with temozolomide and followed up routinely at the study site. 4. willing to sign the informed consent exclusion criteria: 1. currently enrolled in any other clinical study 2. history of any other malignancies 3. refusal to give consent 4. no available tumor tissue for idh analysis.

Keywords: biomarker q cell overall survival progression-free survival
bone demineralization lesions in the injured marrow: efficacy and tolerability of administration early and repeated the zoledronic acid. comparative study, prospective, double-blind controlled (dbmzol)

Conditions: Bone Demineralization Lesions in the Injured Marrow

Summary: subjects with lesion bone marrow are at risk of fracture by fragility bone. the median time to onset of fracture was 8.5 years. fracture increases costs of care, dependency. bone fragility is secondary to hormonal disorders and calcium phosphate, impaired excretion of neuropeptides, vasomotor symptoms associated with the asset that promote bone loss and architectural disorganization. these phenomena occur in the first weeks of development of spinal cord injury and predominate in the distal femur and proximal tibia. from the third year, the demineralization stabilizes, bone mass is estimated to be between 70 and 50% of the initial bone mass, the new equilibrium. no clinical evidence is predictive of fracture risk. a criteria surrogate must be used to assess this risk. there is an association between bone mineral density and fracture risk. the fracture threshold knee was evaluated to 0.87 g/cm2. evaluation of bone mineral density in the distal femur is a predictor of fracture risk. measure reliable and reproducible, easy to perform, it is a good element for monitoring the efficacy of anti-resorptive therapy.


Eligibility criteria:
inclusion criteria: * being diagnosed with a spinal cord injury less than 12 weeks of etiology stable, * level of injury c5 l2, * ais grade a to d. * female or male between 18 and 45 years. * no pregnancy. * no osteoporosis. * good oral health. * good glomerular filtration. * no cons-indication to zoledronic acid. * no drugs affecting bone metabolism exclusion criteria: * pregnancy. * osteoporosis. * cons-indication to zoledronic acid. * drugs affecting bone metabolism

Keywords: bone marrow demineralization lesions,: efficacy and tolerability, zoledronic acid
improving the quality of cryopreserved ovarian tissue reimplantation using platelet-enriched autologous plasma

Conditions: Cryopreservation; Ovary Injury; Infertility, Female; Menopause Ovarian Failure

Summary: the study is aimed to evaluate the effects of intraovarian injection of autologous platelet-enriched autologous plasma on the outcomes of orthotopic transplantation of cryopreserved ovarian tissue.


Eligibility criteria:
inclusion criteria: * request for cryopreserved ovarian tissue transplantation; * premature ovarian failure or irregular mentrual cycles; * negative test for hiv, hbv, hcv, treponema pallidum; * negative pap test; * oncological authorization; * absence of neoplastic contamination in the cryopreserved ovarian tissue; * informed consent exclusion criteria: * neoplastic contamination in cryopreserved ovarian tissue; * history of endometriosis; * endocrinological disorders present and not treated (uncompensated thyroid dysfunction, diabetes (type 1, type 2); * body mass index (bmi) \>30 kg/m2; * circulating platelet level \< 150,000 / mml; * bacterial infection; * ongoing use of anticoagulants; * bleeding diathesis.

Keywords: cryopreserved ovarian tissue ovarian tissue transplantation platelet-enriched autologous plasma ovarian endocrine function livebirths
anlotinib in recurrent or metastatic nasopharyngeal carcinoma patients after failure of no less than second-line therapy

Conditions: Nasopharyngeal Carcinoma

Summary: the purpose of this single arm, phase ⅱ clinical trial is to evaluate the efficacy and safety of anlotinib treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of no less than second-line chemotherapy or targeted therapy


Eligibility criteria:
inclusion criteria: * biopsy proved nasopharyngeal carcinoma; * stage ivb according to american joint committee on cancer(ajcc) edition viii, or recurrent disease after chemotherapy and/or radiotherapy; * 18 years or older; without other malignancy; * proper functioning of the major organs. exclusion criteria: * allergic to anlotinib; * female within gestation period or lactation; * patients received drug of other clinical trial within 4 weeks.
substance use screening among drug user

Conditions: Substance Use

Summary: the purpose of this research is to improve the ability of primary medical staffs in screening and intervention for alcohol, benzodiazepines, and other illicit drug use.

in order to reduce the social and personal harm caused by drugs, it is urgent to strengthen the ability of the primary health institutions in screening and intervention the addictive substances use. firstly, the investigators will invite 10 primary medical staffs and 10 experts in addition to revise the manual of alcohol, smoking, and substance use involvement screening test (assist) and brief intervention (bi). then, the investigators will recruit 100 medical staffs to participate the training of assist and bi. secondly, the researcher will investigate the effects of bi technology in reducing the use of addictive substances, improve the addiction related knowledge of patients through randomized controlled study. finally, the investigators will collect the research information, revise the manual, and promote the training.

Eligibility criteria:
inclusion criteria: 1. aged 18-60 years; 2. the patient to the community medical institutions; 3. assist score is in 12-27, in a moderate risk; 4. voluntary to participate; 5. to agree to complete baseline interviews and follow-up studies. exclusion criteria: 1. unable to complete the questionnaire; 2. serious physical illness, action inconvenience.

Keywords: alcohol,smoking,and substance use involvement screening test brief intervention substance use primary medical and health care institution
needle-free delivery of intralesional triamcinolone for pediatric alopecia areata

Conditions: Alopecia Areata

Summary: this is an interventional pilot study assessing the tolerability of needle-free delivery administration of ilta with the med-jet as an alternative to conventional syringe and needle in patients with patchy pediatric alopecia areata. there will be a total of four (4) or five (5) visits necessary for study participation. the investigators hypothesize that the med-jet will have acceptable pain tolerability, efficacy, safety, and a positive impact on patient quality of life.


Eligibility criteria:
inclusion criteria: * diagnosed with alopecia areata by either: * a board-certified dermatologist, or * dermatology nurse practitioner, or * skin punch biopsy * patient has at least 2 alopecic patches each measuring at least 2 cm2 and are... * located on contralateral body sites or * within the same body site but separated by ≥ 1 cm * patient is a candidate for intralesional triamcinolone. * patient able to give informed assent under irb approval procedures when appropriate. * at least one parent or guardian is able to provide informed consent. exclusion criteria: * patient has alopecia totalis, alopecia universalis, or alopecia areata with ophiasis pattern. * known allergy or hypersensitivity to triamcinolone acetonide * pregnant, breastfeeding, or planning to get pregnant 4 weeks before, during, and 4 weeks after the study. * patient is unable/unwilling to provide informed assent when applicable. * known medical diagnosis or use of a medication that alters pain response at time of injection. * active infection at site designated for injection. * if currently being treated for alopecia areata, the current treatment regimen has been started within less than 4 weeks of screening.

Keywords: pediatric
value of von willebrand factor and copeptin assay in children with febrile seizures at sohag university hospital

Conditions: Febrile Seizure

Summary: febrile seizures are one of the most common clinical diseases in pediatric neurology. it occurs between 6 months and 6 years of age and occurs in \~2-5% of children. according to the age, frequency, duration, and type of seizures fs is divided into simple febrile seizures and complex febrile seizures differentiation between febrile seizures and non-ictal events associated with fever such as shivering or dizziness is challenging. therefore, precise diagnosis of fs after paroxysmal episodes associated with fever is often hindered by the lack of an objective biomarker with the widespread application of technologies, such as molecular biology, in medicine, some biomarkers for predicting or diagnosing fs have attracted attention. imuekemhe et al in 1989 and 1996 found that lactic acid in the serum and cerebrospinal fluid of children with fs was significantly increased . arginin-vasopressin hormone avp released by the pituitary gland, has been shown to be involved in the thermoregulatory response to fever and convulsions although avp is unstable in the peripheral blood and, therefore, unsuited for diagnostic use the c-terminal portion of the avp precursor copeptin has been recognized as a robust marker of avp secretion . wellman et al. found that the serum copeptin and von willebrand factor of children with fs were significantly higher than those of the control group .


Eligibility criteria:
inclusion criteria: * age from 6 months to 6 years. * seizures. * fever (≥38°c). exclusion criteria: * central nervous system infection. * epilepsy. * previous neurological abnormalities. * inborn errors of metabolism. * immunological diseases. * endocrinal diseases (e.g., diabetes mellitus). * obesity. * eating disorders. * gastrointestinal disorders (e.g., diarrhea).
the efficacy and safety of lumbar msat on acute low back pain

Conditions: Low Back Pain

Summary: this study is a single blind, randomized controlled trail. condition/disease: acute low back pain treatment/intervention: motion style acupuncture treatment

"motion style acupuncture treatment(msat)" is a therapeutic technique using acupuncture needle created in jaseng hospital. this treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation. this treatment is known to relieve the pain and increase the range of motion(rom). however, there has been no specific value for the effect of this treatment. so, the investigators will conduct a randomized controlled trials to verify the efficacy and safety of lumbar msat. from march 2021 to december 2021, the investigators will collect 96 inpatients who are suffered from low back pain with the numeric rating scale(nrs) over 5 after injury by acute traffic accident(ta). for experimental group(n=48), the investigators will conduct msat three times(on 2nd, 3rd and 4th day of hospitalization) and other korean medical treatment. for control group(n=48), just korean medical treatment except msat will be conducted. for these two groups, the investigators will compare nrs, visual analogue scale(vas), range of motion(rom), oswestry disability index (odi) and euroqol 5-dimension (eq-5d), patient global impression of change (pgic)."

Eligibility criteria:
criteria: inclusion criteria: * patients who needs hospitalization due to acute low back pain that occurred within 7 days after traffic accident * patients with nrs ≥ 5 for low back pain * patients aged 19-70 years on the date they sign the consent form * patients who provide consent to participate in the trial and return the informed consent form exclusion criteria: * patients with a specific serious disease that may cause spinal pain: malignancy, spondylitis, inflammatory spondylitis, etc. * patients with progressive neurological deficits or with severe neurological symptoms- patients who have had surgery or procedures within the last three weeks * the cause of pain is due to soft tissue disease, not the spine: tumors, fibromyalgia, rheumatoid arthritis, gout, etc. * patients with other chronic conditions that may interfere with the interpretation of the therapeutic effects or results: cardiovascular disease, kidney disease, diabetic neuropathy, dementia, epilepsy, etc. * patients who are taking steroids, immunosuppressants, mental illness drugs, or other drugs that may affect the results of the study * if acupuncture is inadequate or unsafe: patients with hemorrhagic, receiving anticoagulants, severe diabetes and cardiovascular disease * patients who are pregnant or planning to become pregnant * patients with a serious mental illness * patients who are participated in clinical trials other than observational studies without therapeutic intervention. * patients who are difficult to complete the research participation agreement * other patients whose participation in the trial is judged by a researcher to be problematic
pericapsular nerve block in proximal femoral fractures

Conditions: Femoral Fracture

Summary: proximal femoral fractures commonly occur above 50 years and regional anesthesia could be a complement in the perioperative treatment of the patients. the use of pericapsular nerve group block (peng block) has been proposed to reduce pain. however, no studies have explored the efficient of the systemic analgesia associated with peng block in functional limitation in the preoperative period. in this sense, the main goal of this study is to evaluate the effectiveness of systemic analgesia associated with peng block in patients with proximal femoral fractures in the period preceding the surgical procedure.

focus on functional capacity will be measured by the activity measure for post-acute care (am-pac) short version of the "6 clicks", pain intensity will be assessed using the numerical rating scale, and opioid consumption. this study will include 21 patients admitted to the emergency room with proximal femoral fractures.

Eligibility criteria:
inclusion criteria: * patients with unilateral proximal femoral fractures admitted to the emergency room of the hospital sírio-libanes, * aged 18-105 years * with the american society of anesthesiology (asa) physical status i, ii, or iii. exclusion criteria: * allergy to metamizole and/or ropivacaine * history of mental disorders * presence of chronic pain as assessed using the douleur neuropathique 4 (dn4) questionnaire
effects of orotic acid derivatives with or without glutathione on allergic rhinitis

Conditions: Seasonal Allergic Rhinitis

Summary: the purpose of this study is to learn if two nutritional supplements, orotic acid and glutathione will have any effect on the immune system response and if there will be any effect on the symptoms of seasonal allergies. it is our thinking that they will have an positive effect.

current therapy for most immune-based diseases center around the use of anti inflammatory agents, many of which have unpleasant or dangerous side effects. allergic rhinitis affects over 40 million americans and its morbidity results from a combination of physical and psychological symptoms. the primary immunopathology has been defined as an imbalance of th1/th2 cytokines production resulting in increased allergen-specific ige production, mast cell activation and eosinophil recruitment/activity. metallic salts of orotic acid (or), a natural intermediate in pyrimidine nucleic acid synthesis have been utilized to improve the signs and symptoms of a variety of maladies including the common cold, allergies and as preventatives for cancer and heart disease. recent studies have reported that moderate doses of or can mitigate or prevent endocrine and subjective psychological stresses in an acute laboratory stress model. all these findings lead us to hypothesize that or salts administration will alleviate or eliminate the signs and symptoms associated with seasonal ar through a protective effect that involves direct anti-inflammatory immune effects and/or immunomodulation that include leukocyte trafficking, immunoregulatory cytokine balance and/or decrease inflammatory cell activity.

Eligibility criteria:
inclusion criteria: participants must have allergic rhinitis and be skin test positive to bermuda grass, johnson grass, oak tree and/or ragweed, be symptomatic - exclusion criteria: any significant known heath disease: cardiovascular disease, cancer, or any metabolic disorder, smoker -

Keywords: allergic rhinitis